Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus

Transplantation

Volumn 85, Issue 8, 2008, Pages 1212-1215

  Dean, Patrick G ^a   Grande, Joseph P ^a   Sethi, Sanjeev ^a   Park, Walter D ^a   Griffin, Matthew D ^a   Cosio, Fernando G ^a   Larson, Timothy S ^a   Stegall, Mark D ^a  

^a Mayo Clinic   (United States)

Author keywords

Calcineurin inhibitor; Chronic allograft nephropathy; Histology; Kidney transplantation; Randomized clinical trial; Sirolimus

Indexed keywords

IOTALAMIC ACID; RAPAMYCIN; TACROLIMUS;

ADULT; ARTERY DISEASE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FIBROSING ALVEOLITIS; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS;

EID: 42549102730     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31816a8ae6     Document Type: Article

References (18)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
2. Grinyo JM, Cruzado JM. Mycophenolate mofetil and sirolimus combination in renal transplantation. Am J Transplant 2006; 6: 1991.
3. Morales JM. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Kidney Int Suppl 2005; 99: S124.
4. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015.
5. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
6. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153.
7. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234.
8. Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: Benefits and risks. Nephrol Dial Transplant 2006; 21: 562.
9. Lee VW, Chapman JR. Sirolimus: Its role in nephrology. Nephrology 2005; 10: 606.
10. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514.
11. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
12. Diaz Encarnacion MM, Griffin MD, Slezak JM, et al. Correlation of quantitative digital image analysis with the glomerular filtration rate in chronic allograft nephropathy. Am J Transplant 2004; 4: 248.
13. Cosio FG, Am H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411.
14. Cosio FG, Grande JP, Larson TS, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 1130.
15. Moreso F, Lopez M, Vallejos A, et al. Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant 2001; 1: 82.
16. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
17. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747.
18. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776.